Genomic Health Inc. is a life science company focused on the
development and commercialization of genomic-based clinical
diagnostic tests for cancer that allow physicians and patients to
make individualized treatment decisions. Genomic Health Inc. has
a market cap of $1.09 billion; its shares were traded at around
$35.12 with a P/E ratio of 129.4 and P/S ratio of 5.3.
On July 11, 2012, CEO of InVitae Corporation of Genomic Health
) Randal W. Scott sold 30,000 shares at an average price of
$35.39. The total transaction amount is $1,061,70.
In 2000, Randy founded Genomic Health and served as CEO until
2009 and executive chairman until 2012. He is currently director
and has also taken the role of CEO of InVitae Corporation, a
wholly owned subsidiary of the company, which was established in
March this year.
On June 12, 2012, CEO of InVitae Corporation Randal W. Scott sold
30,000 shares of GHDX stock at the average price of $33.54. CFO
Dean L. Schorno sold 4,000 shares of GHDX stock in May, March,
April and February. In May, Director and 10% Owner Julian Baker
bought 854,054 shares of GHDX stock.
Genomic Health reported their 2012 first quarter financial
results. The company announced net income of $777,000 and total
revenues of $58.5 million.
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to